Analytical method development and validation for Desvenlafaxine Succinate by UV-Visible Spectroscopy Method

Abstract

An inhibitor of serotonin-nor-epinephrine reuptake is desvenlafaxine succinate. The medication is marketed as pills to be taken orally. In the current work, an effort has been made to establish two spectrophotometric procedures that are quick, exact, and accurate for estimating desvenlafaxine succinate in bulk and dose form. First order derivative spectroscopy method A involved calculating derivative amplitudes by taking the curve's minima and maxima into account. The wavelength range 200-400nm was used for Method B's area under the curve estimation of Desvenlafaxine succinate. For both approaches, linearity was seen in the concentration range of 160 to 240µg/ml & 60-140 µg/ml (r2 = 0.9986 for method A and r2 = 0.9996 for method B). The statistical validation of the analysis' findings attests to the reliability and repeatability of the techniques. All of the procedures were determined to be easy to use, exact, and accurate, and they may all be used for routine quality control testing of desvenlafaxine succinate both in bulk and in its solid dosage form.